TDC
ACUR

Thompson Davis & Co’s Acura Pharmaceuticals ACUR Stock Holding History

Thompson Davis & Co’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6
Closed – – 1274
2017
Q1 		$0 Hold
6
– – ﹤0.01% 1309
2016
Q4 		$0 Hold
6
– – ﹤0.01% 1278
2016
Q3 		$0 Hold
6
– – ﹤0.01% 1235
2016
Q2 		$0 Hold
6
– – ﹤0.01% 1243
2016
Q1 		$0 Hold
6
– – ﹤0.01% 1250
2015
Q4 		$0 Hold
6
– – ﹤0.01% 1253
2015
Q3 		$0 Hold
6
– – ﹤0.01% 1324
2015
Q2 		$0 Hold
6
– – ﹤0.01% 1308
2015
Q1 		$0 Hold
6
– – ﹤0.01% 1328
2014
Q4 		$0 Hold
6
– – ﹤0.01% 1337
2014
Q3 		$0 Hold
6
– – ﹤0.01% 1322
2014
Q2 		$0 Hold
6
– – ﹤0.01% 929
2014
Q1 		$0 Hold
6
– – ﹤0.01% 899
2013
Q4 		$0 Buy
+6
New +$51 ﹤0.01% 714

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Thompson Davis & Co's ACUR Position: Q2 2017 in Review

Thompson Davis & Co sold out of Acura Pharmaceuticals (ACUR) in Q2 2017, closing a stake of 6 shares.

Thompson Davis & Co first reported a position in ACUR in Q4 2013 and held it in 14 quarters. The position peaked at $0 in Q1 2017. 1 fund tracked by Wall St. Rank holds ACUR as of Q2 2017.

  • Thompson Davis & Co reported no remaining Acura Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 6 Acura Pharmaceuticals shares in Q2 2017.
  • Thompson Davis & Co first reported a position in Acura Pharmaceuticals in Q4 2013 and held it in 14 quarters.
  • Thompson Davis & Co's Acura Pharmaceuticals position peaked at $0 in Q1 2017.
  • 1 fund tracked by Wall St. Rank held Acura Pharmaceuticals as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.